Dr. Mark Rogge Takeda Pharmaceuticals, USA

Mark Rogge, PhD, FCP serves as Vice President and Global Head of Quantitative Translational Science at Takeda Pharmaceuticals, International. He oversees all discovery and development modeling & simulation, clinical pharmacology, imaging, and Bioanalytical Sciences. In this role and throughout his career he has promoted the application of advanced modeling &... read moresimulation to pharmacokinetic and pharmacologic processes in the preclinical and clinical realms, and applied these principles to both efficacy and to safety. His work has encompassed small molecules, glycoproteins, antisense constructs, and most recently, gene/cellular therapy. Mark has given numerous plenary presentations related to drug development at scientific and regulatory conferences; he has more than 80 peer-reviewed publications and invited presentations at scientific symposia. He is Past Chair of the AAPS PPDM Section, Past Chair of BIO’s Safety and Pharmacokinetics scientific advisory section and Past Chair of the Clinical Pharmacology Leadership Group for the International Consortium for Innovation and Quality in Pharmaceutical Development. Mark completed his undergraduate studies at the University of Wisconsin, where he is a Citation of Merit recipient, and completed his graduate work at the University of Michigan.